OGN — Organon & Co. (Stock)

Price: $13.81 · 1 day: +0.44% · 5 days: +0.66% · 1 month: +1.02% · YTD: +92.61%
As of 2026-10-09 20:00 UTC.

52-week range: $5.69 – $13.83 (currently at 100% of the range).

The read

OGN is in an uptrend, momentum firm. $14 is the level overhead; $13.75 the first support below.

6 of 6 technical checks lean bullish.

• Price vs 50-day: above
• Price vs 200-day: above
• 50d vs 200d avg: above
• MACD: bullish
• RSI momentum: 69
• 5-day tape: +0.7%

Key levels

Indicators

Next earnings: 2026-11-09.

Latest OGN news

• Investors Look to Growing Opportunities in the Indian M&A Market — ```json { "summary": "Investment bankers at a JPMorgan conference in Mumbai indicate growing opportunities in India's mergers and acquisitions market. The report captures emerging deal trends on the subcontinent and no (Bloomberg Business, 2026-09-25)
• JPMorgan sees India outbound M&A rising as firms move to secure supply chains — JPMorgan expects Indian outbound M&A to continue rising as companies seek supply chain security amid geopolitical volatility, with deals already nearing $24 billion this year and on track for a record high. Overall India (Reuters, 2026-09-21)
• U.S. Women Seeking Hormone-Free IUDs Come Up Short — The U.S. has had only one copper IUD (Paragard) for decades, while other developed countries offer over a dozen, prompting some women to travel abroad for alternatives. In February 2025, the FDA approved a second copper (The New York Times, 2026-09-18)
• PhaseV Appoints Biopharma Leaders Klaus Beck and Avi Kulkarni to Scientific Advisory Board to Guide Expansion of AI Conductor — PhaseV, a Boston-based clinical development technology company, has appointed Klaus Beck, MD, PhD, PhD, former Chief Medical Officer of Organon, and Avi Kulkarni, PhD, MBA, CEO of InoRx, to its Scientific Advisory Board. (PR Newswire, 2026-09-16)
• Bigger Budgets, Less Relief: 83% of In-House Teams Expect Legal Budgets to Increase in 2027, Yet 55% Still Expect Workload to Outpace Budget — Axiom's 2027 In-House Legal Budget Report, surveying 510 legal and finance leaders, finds that 83% of in-house legal teams expect budget increases in 2027, yet 55% still expect workload to outpace budgets and only 6% bel (PR Newswire, 2026-09-08)
• Biosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™ — According to MarketsandMarkets™, the global biosimilars market is projected to grow from USD 37.39 billion in 2026 to USD 70.79 billion by 2036, representing a compound annual growth rate (CAGR) of 6.6%. North America is (PR Newswire, 2026-09-02)
• Organon & Co. — Form 8-K: 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits — Organon & Co. filed a Form 8-K with the U.S. Securities and Exchange Commission on July 31, 2026. The filing was made under Item 7.01, Regulation FD Disclosure, and Item 9.01, Financial Statements and Exhibits. The compa (SEC EDGAR, 2026-07-31)
• Organon & Co. — Quarterly report (10-Q) — Organon & Co. filed its SEC Form 10-Q quarterly report for Q2 FY2026 on July 31, 2026. The company reported revenue of $1.56 billion for the period ended June 30, 2026, representing a 2% decrease year-over-year. Net inco (SEC EDGAR, 2026-07-31)

Explore more

Interactive OGN chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs